Trust analysts at Winterflood have highlighted their favoured biotech and healthcare trusts, as the sector continues its comeback after the threat of significant political reform was reduced following Donald Trump's win in the US Presidential Election a year ago.
The average discount for the AIC's Biotechnology and Healthcare sector has tightened from a weighted average of 5% a year ago to 0% today, while all but one of the funds in existence for more than a year (BB Healthcare was only launched in December) have outperformed the MSCI World Health Care index, which rose 12.8% over one year to 2 November. Over the period, the biggest riser was the £1.2bn Worldwide Healthcare trust, up 32% in share price terms, followed by sister company Biotech Growth trust, up 26%, according to the analysts. This compares to a smaller rise of 7% and a loss of ...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
